Medication Reconciliation in Oncologic Patients

NCT04796142 — Not applicable, Completed, 100 participants, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

An Integrated Model to Increase Medication Recognition and Reconciliation in Oncologic Patients

Registry	NCT04796142, acronym PROF2
Status	Completed
Phase	Not applicable
Study type	Interventional; na, single group, masking: none, health services research
Enrollment	100 (Actual)
Sponsor	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (Other)
Conditions	Medication Reconciliation
Interventions	medication reconciliation (Other)
Dates	start 2019-06-12, primary completion 2023-06-15, completion 2023-09-15, first posted 2021-03-12, last updated 2024-12-09
Locations	1 site in Italy

-Summary

To improve medication reconciliation in oncologic patients in healthcare transitions through an alliance between a Cancer Institute and the community pharmacies and a new integrated IT platform.

Expand all sections · Collapse all

+Detailed description

This trial will explore the alliance between a Cancer Institute and the community pharmacies to improve medication reconciliation in healthcare transitions, and will validate a new integrated IT platform.

Cancer patients receiving an oncologic treatment will be asked to choose a pharmacy participating to the trial, and to perform the pharmacological survey before every cycle of chemotherapy.

This will be sent through the new IT platform to the electronic medical record of IRST, and the Oncologist will perform the reconciliation.

Data about concomitant medications and possible interactions will be exensively analyzed.

+Arms and interventions

Arm	Type	Interventions	Description
Reconciliation	Experimental	Other: medication reconciliation	Interventional trial without drugs

medication reconciliation (Other): medication reconciliation

+Outcome measures

Primary outcomes

medication recognition and reconciliation maintenance [At day 1 of each cycle of treatment (each cycle might be 14, 21 or 28 days)]: number of reconciliations per patient

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Adult ≥18 years old
* Eastern Cooperative Oncology Group (ECOG) performance status ≤1
* Patients receiving an anticancer treatment
* Clear understanding of the Italian language; written informed consent.

Exclusion Criteria:

\- None

+Locations (1)

Facility	City	Country	Status
Alessandro Passardi	Meldola, FC	Italy

+Publications

Results publication: Passardi A, Serra P, Donati C, Fiori F, Prati S, Vespignani R, Taglioni G, Farfaneti Ghetti P, Martinelli G, Nanni O, Altini M, Frassineti GL, Minguzzi MV. An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study. J Med Internet Res. 2021 Dec 20;23(12):e31321. doi: 10.2196/31321. PMID 34932001

+Investigators

martina minguzzi, Principal investigator, IRCCS IRST

My Notes

Public

To Read Reading Read